t-MDS treatments boost remission with HMA combinations, yet overall survival still lags; experts await breakthrough therapies ...
Azacitidine plus venetoclax boosts response rates in therapy-related high-risk MDS, enabling transplant bridging despite frequent severe cytopenias and infection risk.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果